Brain Calcifications: Genetic, Molecular, and Clinical Aspects

Int J Mol Sci. 2023 May 19;24(10):8995. doi: 10.3390/ijms24108995.

Abstract

Many conditions can present with accumulation of calcium in the brain and manifest with a variety of neurological symptoms. Brain calcifications can be primary (idiopathic or genetic) or secondary to various pathological conditions (e.g., calcium-phosphate metabolism derangement, autoimmune disorders and infections, among others). A set of causative genes associated with primary familial brain calcification (PFBC) has now been identified, and include genes such as SLC20A2, PDGFB, PDGFRB, XPR1, MYORG, and JAM2. However, many more genes are known to be linked with complex syndromes characterized by brain calcifications and additional neurologic and systemic manifestations. Of note, many of these genes encode for proteins involved in cerebrovascular and blood-brain barrier functions, which both represent key anatomical structures related to these pathological phenomena. As a growing number of genes associated with brain calcifications is identified, pathways involved in these conditions are beginning to be understood. Our comprehensive review of the genetic, molecular, and clinical aspects of brain calcifications offers a framework for clinicians and researchers in the field.

Keywords: JAM2; MYORG; PDGFB; PDGFRB; SLC20A2; XPR1; primary familial brain calcification (PFBC).

Publication types

  • Review

MeSH terms

  • Brain / metabolism
  • Brain Diseases* / metabolism
  • Calcinosis* / genetics
  • Calcinosis* / metabolism
  • Calcium / metabolism
  • Humans
  • Molecular Biology
  • Mutation
  • Sodium-Phosphate Cotransporter Proteins, Type III / genetics
  • Xenotropic and Polytropic Retrovirus Receptor

Substances

  • Xenotropic and Polytropic Retrovirus Receptor
  • Calcium
  • SLC20A2 protein, human
  • Sodium-Phosphate Cotransporter Proteins, Type III

Grants and funding

F.L. is supported by grants from Cure SMA, Thompson Family Foundation Initiative (TFFI), Project-ALS, and National Institute of Health (R21NS101575); G.R. is supported by grants from Michael J Fox Foundation, Parkinson’s Foundation, Department of Defense (PD210038), National Institute of Health (R01NS116006).